With just over three weeks into the Epidiolex launch, Piper Jaffray analyst Danielle Brill says she is not surprised that GW Pharmaceuticals provided no specific metrics on yesterday's Q4 update. Management did state that they are pleased with demand and broad initial formulary inclusion, Brill tells investors in a post-earnings research note. The analyst continues to anticipate a strong launch given her interactions with key opinion leaders "who've consistently indicated that demand is high." She keeps an Overweight rating on GW Pharmaceuticals with a $180 price target.